Ph.D., Vice President, Diagnostics, Pfizer Worldwide R&D
Hakan is responsible for development of companion diagnostics (CDx) across Pfizer’s pharmaceutical portfolio. He held positions of increasing responsibility at Pfizer since 1999, most recently focused on development and implementation of Pfizer’s diagnostics strategy. He led Pfizer’s flagship program in CDx for Xalkori® to US approval in 2011. Prior to that, he was at Parke-Davis Pharmaceuticals and worked in biotech in statistical genetics, human genetics and pharmacogenomics fields. He serves as a member of the Board of Personalized Medicine Coalition, and on CA Gov. Brown’s Precision Medicine Advisory Committee. Hakan has authored over 30 referred scientific articles as well as many other papers, abstracts and book chapters. He holds a PhD in Quantitative Genetics from the University of Minnesota where he was a Rotary Ambassadorial Scholar, and his BS and MS degrees are from Ankara University in Turkey. He conducted postdoctoral studies at the University of California-Davis.
Clinical Dx Showcase: Pfizer Worldwide R&D
Pfizer is a pharmaceutical company with a portfolio of products across most disease areas.
Diagnostics in the Precision Medicine Era
Recent developments in companion diagnostics, with data from Pfizer, will be presented to highlight impact of new and established technologies on development of precision medicines.